← Leaderboards
Deanna L Kroetz
University Of California San Francisco
$14,571,308
Attributed
$15,242,521
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,242,521 · 8
By mechanism
R01$9,670,034 · 4
T32$5,536,074 · 2
M01$28,913 · 1
R13$7,500 · 1
Top collaborators
- Nadav Ahituv3 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Maria Almira Correia$15,621,973
- Leslie Z Benet$3,583,449
- Neal L Benowitz$31,329,042
- Elizabeth M. St. Lezin$722,623
- Ralph Curtis Morris$2,933,149
Others in their field
Top investigators on “Regulation”
- Kiyoshi Suyehiro · Iodp Management International, Inc$166,539,344
- David Heimbrook · Leidos Biomedical Research, Inc.$152,164,826
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Nevan J Krogan · University Of California, San Francisco$101,337,442
- Asimah Rafi · Technical Resources Inc$95,881,052
- Richard C Boucher · University Of North Carolina Chapel Hill$83,460,414
Research focus
RegulationPreventionSignal TransductionPathway InteractionsPharmacogeneticsAffectPreventToxic EffectMediatingPharmacotherapySignal PathwayMetabolismGenesCellsPeripheral Nervous System DiseasesQuality Of LifeNeurotoxicityPaclitaxelNeuritesChemotherapy-Oncologic ProcedureNeuronsClinical TrialsChemotherapyMicrotubules
Grant awards (40)
Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity$458,845
R01 · FY2025 · CA · contact PI
Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity$345,461
R01 · FY2024 · CA · contact PI
Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity$396,776
R01 · FY2023 · CA · contact PI
Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity$154,569
R01 · FY2023 · CA · contact PI
Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity$72,055
R01 · FY2023 · CA · contact PI
Clinical Pharmacology, Drug Action and Pharmacogenetics$626,867
T32 · FY2022 · GM · contact PI
Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity$562,905
R01 · FY2022 · CA · contact PI
Contribution of Nuclear S1P Signaling to Microtubule Targeting Agent-Induced Changes in Transcriptional Activity in Human iPS-SNs$61,979
R01 · FY2022 · CA · contact PI
Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity$571,041
R01 · FY2021 · CA · contact PI
Clinical Pharmacology, Drug Action and Pharmacogenetics$548,127
T32 · FY2021 · GM · contact PI
Pharmaceutical Sciences and Pharmacogenomics$453,005
T32 · FY2021 · GM · contact PI
Pharmaceutical Sciences and Pharmacogenomics$447,432
T32 · FY2020 · GM · contact PI
Pharmacogenomics of Microtubule Targeting Agents$526,471
R01 · FY2019 · CA · contact PI
Pharmaceutical Sciences and Pharmacogenomics$441,989
T32 · FY2019 · GM · contact PI
2019 Multi-Drug Efflux Systems GRC/GRS$7,500
R13 · FY2019 · AI · contact PI
Pharmacogenomics of Microtubule Targeting Agents$842,864
R01 · FY2018 · CA · contact PI
Pharmaceutical Sciences and Pharmacogenomics$436,675
T32 · FY2018 · GM · contact PI
Pharmacogenomics of Microtubule Targeting Agents$735,702
R01 · FY2017 · CA · contact PI
Pharmaceutical Sciences and Pharmacogenomics$431,491
T32 · FY2017 · GM · contact PI
Pharmacogenomics of Microtubule Targeting Agents$834,690
R01 · FY2016 · CA · contact PI
Pharmaceutical Sciences and Pharmacogenomics$300,661
T32 · FY2016 · GM · contact PI
Pharmacogenomics of Microtubule Targeting Agents$851,184
R01 · FY2015 · CA · contact PI
Pharmaceutical Sciences and Pharmacogenomics$317,958
T32 · FY2015 · GM · contact PI
Mechanisms of Renoprotection by Soluble Epoxide Hydrolase Inhibition$373,852
R01 · FY2014 · DK · contact PI
Pharmaceutical Sciences and Pharmacogenomics$314,602
T32 · FY2014 · GM · contact PI
Mechanisms of Renoprotection by Soluble Epoxide Hydrolase Inhibition$361,815
R01 · FY2013 · DK · contact PI
Pharmaceutical Sciences and Pharmacogenomics$311,245
T32 · FY2013 · GM · contact PI
Mechanisms of Renoprotection by Soluble Epoxide Hydrolase Inhibition$368,782
R01 · FY2012 · DK · contact PI
Pharmaceutical Sciences and Pharmacogenomics$311,245
T32 · FY2012 · GM · contact PI
Mechanisms of Renoprotection by Soluble Epoxide Hydrolase Inhibition$371,202
R01 · FY2011 · DK · contact PI
PHARMACEUTICAL SCIENCES AND PHAMOCOGENOMICS$289,973
T32 · FY2011 · GM · contact PI
Mechanisms of Renoprotection by Soluble Epoxide Hydrolase Inhibition$464,216
R01 · FY2010 · DK · contact PI
PHARMACEUTICAL SCIENCES AND PHAMOCOGENOMICS$304,804
T32 · FY2010 · GM · contact PI
DIGOXIN TWIN STUDY$13,094
M01 · FY2005 · RR
CYTOCHROME P450 DEPENDENT ARACHIDONIC ACID METABOLISM$258,125
R01 · FY2004 · HL
Impact of Genetics on Digoxin Pharmacokinetics$15,819
M01 · FY2004 · RR
CYTOCHROME P450 DEPENDENT ARACHIDONIC ACID METABOLISM$258,125
R01 · FY2003 · HL
CYTOCHROME P450 DEPENDENT ARACHIDONIC ACID METABOLISM$258,125
R01 · FY2002 · HL
CYTOCHROME P450 DEPENDENT ARACHIDONIC ACID METABOLISM$258,125
R01 · FY2001 · HL
CYTOCHROME P450 DEPENDENT ARACHIDONIC ACID METABOLISM$283,125
R01 · FY2000 · HL